In an earlier report Horowitz et al.57 showed that oral and intravenous glutathione and the glutathione precursors (N-acetylcysteine) attenuated activation of NF-κB, cytokine storm syndrome and respiratory distress syndrome seen in COVID-19 patients with pneumonia. This evidence concerns the gene NFKB1 and COVID-19.